Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced the appointment of Scott M. Wasserman, MD, to its Board of Directors, effective October 19, 2026. Concurrent with the appointment, the Company reported the resignation of Dennis Berman from the Board and his positions as Chair of the Compensation Committee and a member of the Audit Committee, also effective October 19, 2026. The Company stated that Mr. Berman’s resignation was not the result of any disagreement regarding the Company’s operations, policies, or practices.
Dr. Wasserman is currently the Chief Medical Officer of Kailera Therapeutics, a clinical-stage company developing GLP-1-based therapeutics. He brings over two decades of experience in clinical development and company leadership. Previously, he served as Vice President, Global Development and Therapeutic Area Head for Bone, Cardiovascular, Metabolic, and Neuroscience at Amgen, where he led the global development and approvals of Repatha (evolocumab) and was instrumental in the development and U.S. FDA approval of Evenity (romosozumab) and Aimovig (erenumab). Prior to his role at Amgen, Dr. Wasserman was a Venture Partner at Frazier Life Sciences and the CEO and co-founder of Latigo Biotherapeutics.
Dr. Wasserman will serve as a Class III director, holding office until the Company’s annual meeting of stockholders in 2029, or until his earlier death, resignation, or removal. The Board has determined that he is independent under the listing standards of The Nasdaq Stock Market LLC and the rules of the Securities and Exchange Commission. He will also serve as a member of the Compensation Committee.
In connection with his appointment, Dr. Wasserman will receive an initial new director grant of non-qualified stock options to purchase up to 310,000 shares of the Company’s common stock, as well as cash compensation for Board and committee service, in accordance with the Company’s Non-Employee Director Compensation Policy. The Company also noted that Dr. Wasserman entered into an indemnification agreement with the Company consistent with a form previously filed with its most recent Annual Report on Form 10-K.
